Protein Tyrosine Phosphatase 1B (PTP1B, encoded by the PTPN1 gene) is a well-established non-receptor tyrosine phosphatase that acts as a primary negative regulator of the insulin and leptin receptor signaling pathways. Historically classified as "undruggable" due to the highly charged nature of its catalytic active site, PTP1B has emerged as a high-value target for Type 2 Diabetes, obesity, non-alcoholic steatohepatitis (NASH), and oncology (immunotherapy). Modern drug discovery focuses heavily on allosteric inhibitors, PROTAC degraders, and covalent modifiers to bypass classical active-site selectivity challenges.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for PTP1B (PTPN1) drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | Recombinant Human PTP1B (PTPN1) Active Domain / Mutant Proteins High purity (>95%), Endotoxin controlled, Sequence Verified. Suitable for enzymatic assays and SPR. |
View PTPN1 Products |
| Gene Delivery | PTPN1 Promise-ORF / Lentivirus Particles Full-length ORF for stable cell line construction and in vitro overexpression studies. |
View PTPN1 Products |
| Benchmark Ab | Anti-PTP1B Recombinant Control Antibody Sequence-verified positive control for Western Blot, ELISA, and immunoprecipitation. |
View PTPN1 Products |
| Validator | PTPN1 siRNA Set Target-specific knockdown pool for functional validation and phenotypic assays. |
View PTPN1 Products |
| Related Target A | PTPN2 (TCPTP) Highly homologous phosphatase (74% catalytic identity). Essential counter-screening target to prevent off-target toxicity. |
View PTPN2 Products |
| Related Target B | INSR (Insulin Receptor) Direct downstream substrate of PTP1B. Used to validate signaling restoration in cell-based assays. |
View INSR Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Selectivity over TCPTP (PTPN2) | High-purity human PTP1B and PTPN2 recombinant protein panels strictly verified by mass spectrometry. |
| Allosteric Site Mapping | Conformationally stable wild-type and catalytic-inactive (C215S) "substrate-trapping" mutant proteins. |
| Lack of Controls | Sequence-derived recombinant benchmark antibodies and validation-grade siRNA sets included. |
| False Positives in Screening | Endotoxin-controlled, detergent-compatible formulations to eliminate non-specific aggregation artifacts. |
Live PTP1B R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for PTP1B therapeutics is intensifying, with major players shifting focus from traditional active-site small molecules to allosteric inhibitors and targeted protein degradation (PROTACs). As first-generation active-site inhibitors failed due to poor cell permeability and lack of selectivity against TCPTP, the next wave of R&D is targeting allosteric pockets (e.g., the C-terminal hydrophobic site) and leveraging PTP1B inhibition as an intracellular immune checkpoint in oncology.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Allosteric Small Molecule | DepYmed, ERX Pharmaceuticals, AbbVie | Type 2 Diabetes, NASH, Breast Cancer | Selectivity Screening (Need high-purity PTP1B vs. PTPN2 proteins) |
| PROTAC Degraders | Academic institutions, Biotech startups | Solid Tumors, Inflammatory Diseases | Degradation Kinetics (Need Lentivirus for stable reporter cell lines) |
| Antisense Oligonucleotides | Ionis Pharmaceuticals | Severe Obesity, Metabolic Syndrome | Target Knockdown Verification (Need high-specificity siRNA sets) |